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Abstract
Background: Novel immunosuppressive therapy facilitates long term allograft survival, but acute tubular necrosis and
ischemia-reperfusion during transplantation can compromise allograft function. These processes are related to oxidative
stress which activates poly- (ADP-ribose) polymerase (PARP) contributing to the activation of cell death pathways. Here we
raised the possibility that PARP inhibition curbs cell death pathways and shifts kinase signaling to improved graft survival.
Methods Findings: In an acute rat kidney rejection model, we provided evidence that the PARP inhibitor 4-hydroxy-
quinazoline (4OHQ) attenuates rejection processes initiated oxidative/nitrosative stress, nuclear poly-ADP-ribosylation and
the disintegration of the tubulo-interstitial structures. The PARP inhibitor attenuated rejection processes induced pro-
apoptotic pathways by increasing Bcl-2/Bax ratio and suppressing pro-apoptotic t-Bid levels. In transplanted kidneys, the
cell death inducing JNK1/2 is normally activated, but PARP inhibition suppressed this activation with having only modest
effects on ERK1/2 and p38 MAP kinases. In untreated transplanted kidneys, no significant alterations were detected in the
cytoprotective PI-3K-Akt pathway, but the PARP inhibitor significantly activated Akt (by S473 phosphorylation) and
suppressed GSK-3b, as well as activated acute NF-kappaB activation contributing to graft protection.
Conclusion: These data show the protective role of PARP inhibition on graft survival by attenuating poly-ADP-ribosylation,
oxidative stress, suppressing pro-apoptotic and increasing anti-apoptotic protein level, and by shifting MAP kinases and PI-
3-K-Akt pathways to cytoprotective direction. Thus, addition of PARP inhibitors to standard immunosuppressive therapies
during kidney transplantation may provide increased protection to prolong graft survival.
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Introduction
Kidney transplantation is the best choice for patients with end-
stage kidney disease. Due to cellular and humoral immune
response, acute kidney damage however may be an important
cause for graft loss [1]. Rejection is often characterized and
mediated by the presence of at least 4 types of committed helper T
cells (T helper (Th)1, Th2, Th17, and regulatory T cells) in the
interstitial, tubular, and glomerular compartments [1,2]. The
presence of these cells is often associated with vasculitis, deposition
of immunoglobulins in peritubular capillaries [3]. An activation of
the complement cascade [4] and the presence of proinflammatory
cytokines (e.g. TNF-a and IL-17) may also be involved. Anti-
inflammatory cytokines, such as TGF-b, the transcription factor of
regulatory T cells and FoxP3 on the other hand facilitate better
transplant survival [3]. Allograft damage may be also caused by
leukocyte infiltration, recruitment of neutrophils and monocytes
on activated endothelial cells contributing to tubular interstitial
inflammation and oxidative stress. These processes lead to cell
death and chronic dysfunction [5]. Other types of injuries, such as
ischaemia-reperfusion, acute rejection and hyperacute rejection
are related to inflammation and oxidative stress affecting the
outcome of transplantation [4]. Earlier data demonstrated that
higher oxidative stress markers in the serum of transplanted
patients generally result in less functional kidney indicating the
significance of oxidative stress in the decline of graft function [6].
It is known, that components of standard immunosuppressive
therapy (e.g. Cyclosporine A and Tacrolimus) cause oxidative
stress and activates MAPK signaling which lead to glomerular
dysfunction and subsequent nephrotoxicity [7,8]. Therefore, a
therapy to protect transplanted kidney tissues from oxidative stress
and oxidative stress related processes in addition to attenuation of
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rejection processes by immunosuppressive therapy may have
clinical significance. Efforts to activate cytoprotective pathways
using carbamylated erythropoietin [9] or to possess antioxidant
activity via liposomal curcumin [10] support our hypothesis.
Poly- (ADP-ribose) polymerase (PARP)-1 is a high copy number
nuclear enzyme which is activated by DNA-breaks and catalyzes
the poly-ADP-ribosylation of nuclear proteins utilizing NAD+
[11,12]. Oxidative stress via the induction of DNA breaks can
activate PARP leading to NAD+ and ATP depletion followed by
necrotic cell death [13]. In addition, PARP activation through the
destabilization of mitochondrial outer membranes promotes the
release and nuclear translocation of Apoptosis-Inducing Factor
(AIF) and Endonuclease G leading to apoptosis [14,15]. There-
fore, PARP inhibitors can be used to prevent oxidative stress
induced cell death [13–15]. Oxidative stress induced activation of
PARP promotes JNK and p38 MAPK activation while PARP
inhibitors suppresses their activation [16–18]. We found that
inhibition of PARP in oxidative stress activates the expression of
MAP kinase phosphosphatase-1 (MKP-1/Dusp1) which is the
major phosphatase, which dephosphorylates and inactivates the
MAP kinases [19]. From these data we can conclude that PARP
inhibitors have the potential to protect different tissues from
oxidative stress [11,20,21], and can regulate a favorable way MAP
kinases [19] and inflammatory processes [22].
Therefore, PARP inhibitors have protective effects in various
oxidative stress related disease-models by preventing compromised
energy status and by preventing other cell death promoting effects
of PARP activation [11, 12, 23, 24). Excessive activation of PARP
by stress stimuli, such as reactive oxygen species (ROS) formation
has been associated with the pathogenesis of various diseases,
including cerebral ischemia, Parkinson’s disease [25,26], ischemia-
reperfusion (IR) - induced cardiac dysfunction [27,28], develop-
ment of diabetic complications [29] and angiogenesis [30].
Studying the renal graft dysfunction in acute rat rejection model
we found PARP inhibitor 4-hydroxyquinazolone (4OHQ) has
protective effects. It prevents disintegration of the tubulointerstitial
structures, decreases oxidative stress markers, increases anti-
apoptotic Bcl-2 levels, suppresses cell death by inducing JNK
activation and activates the cytoprotective PI-3K-Akt pathway.
Our data suggest adding PARP inhibitors to immunosuppressant
regiments during kidney transplantation may be advantageous in
the acute rejection period to protect the graft against ischemia-
reperfusion and other types of oxidative stress induced damages.
Materials and Methods
Materials
Protease inhibitor cocktail and all chemicals for cell culture were
purchased from Sigma Aldrich Co. (Budapest, Hungary). PARP
inhibitor 4-hydroxiquinazoline was purchased from Sigma-Aldrich
as previously [31,32]. All reagents were of the highest purity
commercially available.
Animals and Renal Transplantation
Inbred male rats from Charles River Laboratories GmbH
(Hungary) were used for all transplant experiments. Fisher 344
rats; body weight (bw) 230 to 250 g served as donors for kidney
transplants. Lewis rats (LEW RT1l; bw, 200 to 230 g) served as
recipients. Ureters were directly inserted into the bladder. All
animals were fed with standard rat chow and had free access to tap
water. All experiments conformed to the Guide for the Care and
Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85-23, revised 1996),
and was approved by the Animal Research Review Committee of
the University of Pecs Medical School.
Renal transplantation was performed by a technique modified
from [33]. Animals were anaesthetized with i.p. ketamine
hydrochloride. The aorta of the donor animal was cannulated
and the abdominal organs were perfused in situ with 10 ml of
hyperosmotic citrate kidney perfusion solution (SoltranH, Baxter).
Right kidney was removed and deep frozen as control. Left kidney
was removed with a long ureter. The recipient operation was
performed via median laparotomy approach. The artery of the
graft was anastomosed end-to-side to the infrarenal aorta using 9-0
interrupted suture (ProleneH, Ethicon). The renal vein of the graft
was anastomosed using the same technique to the infrarenal vena
cava inferior. The ureter was directly inserted into the bladder.
The recipient animal’s native kidneys were left intact. The cold
ischemia time varied between 30 and 50 minutes. The anastomosis
time was between 40 and 50 minutes in every group.
Experimental Protocol and Experimental Groups
4-hydroxyquinazoline (Sigma) was dissolved in water diluted to
0.9% sodium chloride and injected subcutaneously twice a day at a
dose of 20 mg/kg bw in all treated animals. The experimental
groups were as follows: group 1: Fisher 344 rats injected with 0.9%
sodium chloride. 2. Fisher 344 rats injected with 20 mg/kg bw 4-
hydroxyquinazoline in 0.9% sodium chloride. 3. Fisher 344
kidneys into LEW rats, injected with 0.9% sodium chloride. 4.
Fisher 344 kidneys into LEW rats injected with 20 mg/kg bw 4-
hydroxyquinazoline in 0.9% sodium chloride. After 10 days rats
were sacrificed by an overdose of i.p. ketamine hydrochloride,
kidneys were removed and subjected to morphological and
biochemical analysis.
Renal histology
Renal allografts were removed in deep anesthesia, quickly
blotted free of blood, weighed, and processed as required for
histology and immunohistology. Kidneys were fixed in 10%
formalin, embedded into paraffin and 5 mm thin sections were cut
with microtome. Sections were stained with hematoxylin–eosin
and digital photos were taken. Haematoxylin-eosin staning and
periodic acid Schiff (PAS) reaction was also performed.
Immunohistochemical staining
Slides were deparaffinized in xilene, rehydrated in graded
ethanol series, and washed in distilled water. Heat induced epitope
retrieval was performed by boiling the tissue sections in citrate
buffer (HISTOLSH Citrate Buffer, cat# 30010; Histopathology
Ltd.) in a microwave oven at 750 W followed by cooling at room
temperature for 20 minutes. Slides were washed in Tris buffered
saline (TBS) solution (pH = 7,6) followed by blocking of
endogenous peroxidase (Peroxidase blocking, cat#30012, Histo-
pathology Ltd.) for 10 minutes at room temperature. Slides were
washed in TBS. Nonspecific sites were blocked (Background
Blocking Protein Solution, cat#30013, Histopathology Ltd.) for 10
minutes at room temperature. Without washing, the following
primary antibodies were applied: anti-bax (Lab Vision/Thermo
Fischer Scientific, cat# RB-9206, in 1:200 dilution), anti-bcl-2
(Lab Vision/Thermo Fischer Scientific, cat# MS-123, in 1:100
dilution), anti-Nitrotyrosine (Milliopre, cat#AB5411 in 1:500
dilution). Incubation with the primary antibodies was performed
for 1 hour at room temperature followed by washing in TBS.
Secondary antibody (HISTOLSH -R Detection System, anti-
rabbit, cat# 30011.R; and HISTOLSH -M Detection System,
anti-mouse, cat# 30011.M Histopathology Ltd.) was applied for
30 minutes at room temperature followed by repeated washing in
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TBS. Sections were incubated with 3-amino-9-ethylcarbazol
(HISTOLSH -Resistant AEC Chromogen/Subsrtate System, cat#
30015.K, Histopathology Ltd.) or 3,3’-Diaminobenzidine (HIS-
TOLSH DAB Chromogen/Subsrtate System, cat#30014.K,
Histopathology Ltd.), washed in distilled water, counterstained
with haematoxylin followed by incubation in tap water. Negative
control was incubated with antibody diluent instead of the primary
antibody and applying anti-rabbit or anti-mouse secondary
antibody. Sections were then dehydrated, cleared in xylene and
mounted with permanent mounting medium.
Morphometric analysis
Adobe Photoshop program was used to mark the positive area
in the immunohistochemistry manually, then converted to black,
while the remaining area to white. For each image, the ‘‘area of
interest’’ as well as the total image area were highlighted, and
measured using Scion Image program. Finally, the ratio of ’’area
of interest’’/total image size was calculated and expressed as
percentage. Comparison of means of the treatment groups was
carried out using ANOVA with Bonferroni’s post-hoc test. A value
of p,0.05 was considered as statistically significant.
Immunoblotting
Kidney samples were homogenized in ice-cold isotonic Tris
buffer (50 mM, pH 8.0) containing 0.5 mM sodium metavana-
date, 1 mM EDTA, and a protease inhibitor cocktail (1:1000;
Sigma–Aldrich) as described previously [19]. Proteins and
phosphorylation sites were determined from the tissue homoge-
nates after sonication. Proteins were precipitated by trichloroace-
tate, washed three times with 220 uC acetone, dissolved in
Laemmli sample buffer, separated on 12% SDS–polyacrylamide
gels, and transferred to nitrocellulose membranes. After being
blocked (2 h with 3% nonfat milk in Tris-buffered saline), the
membranes were probed overnight at 4 uC with antibodies
recognizing the following antigens: phospho-JNK (T183/Y185),
phospho-p38 MAP kinase (Thr180/Tyr182), phosphor-ERK1/2
(Thr202/Tyr204), phosphor-Akt (S473), Akt, phosphor-GSK-
3beta (Ser9), Bcl-2and Bax (Cell Signaling Technology), t-Bid
(Santa Cruz), actin (Sigma), NF-kappaB, phospho-NF-kappaB
(Ser536) (Cell Signaling) Primary antibodies were used in 1:1000
dilution. For nuclear NF-kappaB determination kidneys were
disrupted and the nuclei were separated as described before [29].
Anti-poly-ADP-ribose monoclonal antibody was a gift from
Laszlo Virag (Debrecen, Hungary). The membranes were washed
six times for 5 min in Tris-buffered saline (pH 7.5) containing
0.2% Tween before addition of goat anti-rabbit horseradish
peroxidase-conjugated secondary antibody (1:3000 dilution; Bio-
Rad). The protein bands were visualized with enhanced chemi-
luminescence labeling using an ECL immunoblotting detection
system (Amersham Biosciences). Developed films were scanned
and the pixel volumes of the bands were determined using the
NIH ImageJ software, with the values in ratios of intensity. Each
experiment was repeated a minimum of three times.
Kidney lysates from 20 mg tissues were prepared and incubated
with 100 mL of magnetic beads bound Histon H1 antibody.
Samples were incubated overnight at 4uC with gentle mixing, and
magnetic beads were washed three times with TBS–Tween 20
(0.05%) prior to the addition of 30 mL sample buffer. Histon H1
content and poly-ADP-ribosylation levels were determined by
immunoblotting.
Statistical analysis of immunoblot data
Five animals were allocated to each groups. All data were
expressed as means6SEM from at least triplicate determinations.
ANOVA with a post hoc correction was used to determine
differences. The Student t test was used to compare the mean
values from the two groups. Differences were regarded as
significant when the P value was ,0.05.
Results
Histopathology of transplanted kidneys
As it is demonstrated by HE and PAS slides, signs of vascular
and cellular-interstitial rejection were seen in the untreated
transplanted as well as in the PARP-treated transplanted rats,
but not in the other two groups of experimental animals indicating
that PARP inhibitor does not suppress the immune system. There
were no significant histopathological alterations in the renal
specimens of the control and the PARP-treated, non-transplanted
rats. The transplanted kidneys showed disintegration of the
tubulointerstitial structures as indicated by HE as well as PAS
slides. On the contrary, less affected structures also in the
tubulointerstitial region were observed in the PARP-treated
transplanted animals (Fig. 1). These data indicate a protective
role of PARP inhibition in the tubulointerstitial region.
Effect of PARP inhibition on poly-ADP-ribosylation in
transplanted kidneys
It is well known that PARP poly-ADP-ribosylates histones [34].
Thus, to investigate the role of PARP during organ transplantation
we studied histone poly-ADP-ribosylation in transplanted kidneys.
Our results reveal that, ADP-ribosylation is highly detectable in
transplanted kidneys when compared to controls (Fig. 2A, B).
Comparing to the high signal intensity in the transplanted
untreated kidneys PARP inhibition significantly decreased the
ADP-ribosylation of histonH1 (Fig. 2A, B).
Effect of PARP inhibition on the protein nitration in
transplanted kidneys
In untreated control and PARP inhibitor treated control
kidneys, no significant tyrosine nitrations were observed (Fig.
Figure 1. Effect of PARP inhibitor on the structure of tubulo-
interstitial system of transplanted kidneys. Kidneys were fixed in
10% formalin, embedded into paraffin and 5 mm thin sections were cut
with microtome. Sections were stained with hematoxylin–eosin (HE).
Two representative images of different magnifications are presented for
untreated unoperated (Cont.), 4OHQ treated unoperated (Cont.+4OHQ),
untreated transplanted (Transp.), and 4OHQ treated transplanted
kidneys.Scale bar: 100 and 20 mm for upper and lower row, respectively.
doi:10.1371/journal.pone.0081928.g001
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2C, D). However, marked nitrotyrosine positivity was detected in
the transplanted untreated kidneys indicating that ischemia-
reperfusion during transplantation followed by immunological
rejection cause significant oxidative stress and nitration (Fig. 2C,
D). In the transplanted PARP-treated kidneys, nitrotyrosine
positivity was significantly weaker (Fig. 2C, D) suggesting that
PARP inhibition decreased oxidative/nitrosative stress in trans-
planted kidneys.
Effect of PARP inhibition on pro- and anti-apoptotic Bcl-2
analogues
Control kidneys with or without PARP inhibitor showed only
insignificant Bax staining (Fig. 3A, B). In transplanted -untreated-
kidneys, a strong, granular Bax positivity was observed in the
tubular epithelial cells. Our observations are not surprising, since
several works suggest that oxidative stress facilitates Bax expression
[35,36]. Inhibition of PARP in transplanted kidneys significantly
suppressed Bax expression in the tubulointerstitial region (Fig. 3A,
B), which is most likely related to decreased oxidative stress, or
altered signaling of PARP inhibition [19]. Slight circumscribed
immunostaining of BCL-2 in the peritubular capillary endothelial
as well as in some tubular epithelial cells were seen in untreated
control kidneys, PARP inhibitor treated control kidneys and in the
transplanted untreated kidneys (Fig. 3C, D). Strong Bcl-2 positivity
was present in the tubular epithelial cells of PARP-treated
transplanted kidneys. That is, PARP inhibition significantly
increased the Bcl-2/Bax ratio shifting the cells fate from apoptosis
to survival.
The results from total kidney homogenates support those from
the immunohistology, namely, Bax increases in transplanted
kidneys and Bcl-2 in the PARP inhibitor-treated transplanted
kidneys (Fig. 4A, B). Therefore, PARP inhibition shifts Bcl-2/Bax
ratio to Bcl-2 direction facilitating cell survival. We also
investigated the expression of t-Bid, a molecule absent in control
kidneys (treated or untreated by PARP inhibitor) (Fig. 4A, B). In
the transplanted kidneys without PARP inhibitor treatment, t-Bid
was very high, while PARP inhibition in transplanted kidneys
decreased t-Bid level significantly (Fig. 4A, B). These data indicate
PARP inhibition protects transplanted kidneys by shifting Bcl-2/
Bax and by suppressing t-Bid.
Effect of PARP inhibition on cytoprotective PI-3-K-Akt
pathway and NF-kappaB activity
In transplanted kidneys, the rejection processes are related to
oxidative stress, which influences the activation of PI-3K-Akt
pathway. Our data suggest (Fig. 5A, B) that transplantation
significantly increases the quantity of total Akt-1 when compared
to controls independently of PARP inhibitor treatment. However,
the level of activated p-Akt-ser473 was significantly increased after
PARP inhibition in transplanted kidneys when compared to
untreated transplanted kidneys (Fig. 5A, B). GSK-3beta is a well
known downstream target of Akt. Akt inactivates GSK-3beta by
Figure 2. Effect of PARP inhibitor on poly-ADP-ribosylation (PAR) and protein nitration in transplanted kidneys. (A) Immunoblot
analysis of poly-ADP-ribosylated HistonH1. HistonH1 was immunoprecipitated with anti-histonH1 antibody, dissolved in sample buffer, subjected to
electrophoresis and blotting. Poly-ADP-ribose was detected by anti-PAR antibody. (B) Quantitative analysis of immunoblot samples (C) Representative
images of nitrotyrosine immunohistochemistry. Brown color indicates nitrotyrosine positivity; scale bar: 50 mm. (D) Quantitative analysis of
immunoblot samples. *: p,0,0001 untreated transplanted kidneys compared to others. ANOVA, Bonferroni post hoc test. Mean6SD. All details
described under Materials and Methods.
doi:10.1371/journal.pone.0081928.g002
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phosphorylation at serine 9, preventing GSK-3beta induced
mitochondrial permeability transition and cell death [37]. Our
data indicate PARP inhibitor inactivates GSK-3beta by phos-
phorylation at serine 9 in transplanted kidneys (Fig. 5A, B),
suppressing GSK-3beta / mitochondria mediated cell death
pathway. Next, nuclear NF-kappaB quantity and phosphorylation
were determined (Fig. 5C, D). While the quantities in control
kidneys were undetectable, transplanted samples contained
increased levels of the protein. PARP inhibitor treatment further
increased NF-kappaB levels when compared to untreated trans-
planted kidney samples (Fig. 5C, D). We found activating
phosphorylation of NF-kappaB at Ser 536 was altered similarly.
In control samples p-NF-kappaB were undetectable, in trans-
planted kidneys it was higher. PARP inhibitor treatment further
increased p-NF-kappaB levels in the nuclei of transplanted
kidneys.
Effect of PARP inhibition on MAP kinases in transplanted
kidneys
We analyzed three branches of the MAP kinases; ERK, JNK
and p38. In the control organs, PARP inhibitor caused a decrease
in ERK1/2 phosphorylation (Fig. 6A, B), while in the transplanted
kidneys PARP inhibitor did not affect significantly ERK1/2
activation. While activation/phosphotylation of p38 MAP kinase
in control hearts was undetectable, its phosphorylation increased
upon transplantation. PARP inhibition further increased its
activation (Fig. 5A, B). JNK phosphorylation was undetectable
in control kidneys while JNK1/2 was significantly increased in
transplanted kidneys. PARP inhibition suppressed their phosphor-
ylation and activation (Fig. 6A, B). This effect of PARP inhibitors
on the molecule might have mechanistic significance since JNK1
activation is capable of mitochondrial membrane destabilization
and induction of cell death [38,39].
Figure 3. Effect of PARP inhibitor on the Bax and Bcl-2 immunohistology in transplanted and control kidneys. (A) All images show Bax
immunohistochemistry, brown color indicates Bax positivity, scale bar: 20 mm. (B). Quantitative analysis of Bax immunohistochemistry samples *:
p,0.0001 untreated transplanted kidneys compared to others. ; **: p,0.0001 PARP inhibitor treated transplanted kidneys compared to others.
ANOVA, Bonferroni post hoc test. Mean6SD. (C) All images show Bcl-2 immunohistochemistry, brown color indicates Bcl-2 positivity, scale bar:
20 mm. All details described under Materials and Methods. (D) Quantitative analysis of the Bcl-2 immunohistochemistry. *: p,0,0001 transplanted and
PARP-treated kidneys compared to others. ANOVA, Bonferroni post hoc test. Mean6SD. All details described under Materials and Methods.
doi:10.1371/journal.pone.0081928.g003
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Discussion
Oxidative stress plays a significant role both in acute and
chronic phases of kidney rejection. Causes may be ischemia-
reperfusion induced oxidative stress, inflammatory cytokines or
monocyte/macrophage produced reactive oxygen species [3,6,40].
The critical role of oxidative stress in rejection is supported by the
observations that N-acetylcysteine prevents early rejection in
animal models [41]. In addition, numerous human data indicate
N-acetylcysteine improves graft function in transplanted patients
[42–44]. Popular immune-suppressive drugs (tacrolimus, cyclo-
sporine A) induce oxidative stress in long-term treatment
contributing to the death of nephrons compromising long-term
graft injury [7,8]. Therefore, molecules that prevent oxidative
stress induced cell damages may be important to preserve graft
function.
It is well documented that oxidative stress activates PARP-1 by
inducing DNA damage and single stranded DNA break formation
[16,45]. This activation may affect unfavorable signaling pathways
(activation of JNK and p38 MAP kinase and suppression of Akt
activation) that leads to cell death [34,46]. Furthermore, PARP
activation destabilizes the mitochondrial membrane systems
[14,18] resulting in release of pro-apoptotic proteins [47,48].
Although PARP inhibitors were applied before during heart
transplantation [49–51], there is no evidence about their effect on
the kidney graft survival. Thus, we assumed PARP inhibition
might be advantageous for kidney graft survival by suppressing cell
death pathways and affecting kinase cascades in a favorable way.
We used the water soluble PARP inhibitor, 4OHQ as
previously [16,32]. Prolonged suppression of PARP activity by
impeding DNA repair could be deleterious as it was shown in anti-
cancer studies [52]. On the other hand, inhibiting oxidative stress
induced overactivation rather than physiological activity of the
enzyme did not result in significant pathological alteration even
during very long exposures [16,21,32]. To this day, specificity of
PARP inhibitors is elusive. Most likely, nobody tested any PARP
inhibitor on all members of the PARP family. However, PARP-1 is
considered to be responsible for about 90% of poly-ADP-
ribosylation in mammalian cells [53]. Furthermore, we and others
found that various PARP inhibitors and PARP-1 specific non-
pharmacological inhibition of the enzyme such as PARP-1 siRNA
or overexpression of PARP-1 DNA binding domain resulted in
basically identical effects in different sytems [19,46,54].
Supporting our hypothesis, results in Fig. 1 indicate significant
protection against disintegration of the tubulointerstitial structures
in PARP inhibitor treated transplanted kidneys. We found the
studied aspects of the molecular background to be similar to the
mechanism demonstrated in other oxidative stress models [16–
Figure 4. Effect of PARP inhibitor on Bcl-2, Bax and t-Bid protein levels in transplanted and control kidney samples. (A) Effects of
PARP inhibitor on the Bcl-2, Bax and t-Bid protein levels in control and transplanted kidneys determined using immunoblotting with protein-specific
primary antibodies. Actin was used as loading control. Representative blots of at least three parallel experiments are presented. (B) The bar diagrams
represent pixel volumes of Bcl-2 bands. The bands were normalized to the appropriate actin band. *p,0.001 transplanted PARP inhibitor treated
samples compared to other samples. The vertical axis represents pixel volume means6SEM of the scanned bands on the immunoblots in arbitrary
units. The bar diagrams represent pixel volumes of Bax bands. The bands were normalized to the appropriate actin band. *p,0.01 transplanted PARP
inhibitor treated samples, or transplanted untreated samples compared to control untreated and control PARP inhibitor treated samples. ** p,0.05
transplanted PARP inhibitor treated samples compared to transplanted untreated samples. The bar diagrams represent pixel volumes of t-Bid bands.
The bands were normalized to the appropriate actin band. *p,0.01 transplanted PARP inhibitor treated samples, or transplanted untreated samples
compared to control untreated and control PARP inhibitor treated samples. ** p,0.05 transplanted PARP inhibitor treated samples compared to
transplanted untreated samples.
doi:10.1371/journal.pone.0081928.g004
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Figure 5. Effect of PARP inhibitor on the PI-3-kinase – Akt pathway and Akt level in transplanted and control kidney samples. (A)
Effects of PARP inhibitor on the Akt1 protein, and phosphorylation of Akt1 and GSK-3 b in control and transplanted kidneys determined using
immunoblotting with protein and phospho-specific primary antibodies. Actin was used as loading control. Representative blots of at least three
parallel experiments are presented. B. The bar diagrams represent pixel volumes of phosphorylated Akt (serine 473) in kidney samples. The bands
were normalized to the appropriate actin band. *p,0.01 transplanted PARP inhibitor treated samples compared to other samples. Difference
between control samples (independently of PARP treatment) and transplanted untreated kidney samples were not significant. The bar diagrams
represent pixel volumes of GSK-3b (serine 9) phosphorylation bands. The bands were normalized to the appropriate actin band. *p,0.001
transplanted PARP inhibitor treated samples compared to control PARP inhibitor treated, or untreated samples. **p,0.05 untreated transplanted
kidney samples compared to control samples (independently of PARP treatment. *** p,0.01 transplanted PARP inhibitor treated samples compared
untreated transplanted samples. The bar diagrams represent pixel volumes of Akt1 protein bands. The bands were normalized to the appropriate
actin band. *p,0.001 transplanted kidney samples (independently of PARP inhibitor treatment) compared to control kidney samples (independently
of PARP inhibitor treatment). (C) Effects of PARP inhibitor on nuclear NF-kappaB and p-NF-kappaB leveles in control and transplanted kidneys
determined by immunoblotting with protein and phospho-specific primary antibodies. Actin was used as loading control. Representative blots of at
least three parallel experiments are presented. (D) The bar diagrams represent pixel volumes of nuclear NF-kappaB protein bands. The bands were
normalized to the appropriate actin band. *p,0.01 transplanted PARP inhibitor treated, or untreated, samples compared to control PARP inhibitor
treated, or untreated control samples. **p,0.05 untreated transplanted kidney samples compared to PARP inhibitor treated transplanted kidney
samples. The bar diagrams represent pixel volumes of nuclear p-NF-kappaB bands. The bands were normalized to the appropriate actin band.
Effect of PARP-Inhibitor in Kidney Transplantation
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18,27]. PARP inhibition decreased the predominantly PARP-1
mediated [12] nuclear poly-ADP-ribosylation (Fig. 2a, B) and
oxidative/nitrating stress seen as decreased nitrotyrosine staining
in PARP inhibitor treated transplanted kidney samples (Fig. 2C,
D). This is in accordance to our previous studies in various
oxidative stress model systems [18,32,27,55]. PARP inhibition also
increased the expression of Bcl-2 and decreased the Bax expression
in transplanted kidneys (Fig. 3A, B) when compared to controls.
That is, suppressing the proapoptotic Bax and activation of the
expression of anti-apoptotic Bcl-2 clearly promote survival and
help to maintain tubulointerstitial structures as demonstrated here
for the first time.
The mechanism of how PARP inhibitors modulate the
expression of Bax and Bcl-2 is not clear. Only recent data indicate
Bax expression is activated by p53 in oxidative stress [56]. Also,
PARP-1 poly-ADP-ribosylates p53 and prevents its Crm1
dependent nuclear export [57]. Therefore, inhibition of PARP-1
may prevent poly-ADP-ribosylation of p53 initiating its Crm1
mediated export from the nucleus and so attenuates p53
dependent gene expressions. PARP inhibition modulates apoptotic
and necrotic cell death by mitochondrial permeability transition
and by AIF release [48,49]. Our observations that PARP
inhibitors enhance Bcl-2 and Bax ratio suggest this could be
another pathway by which they promote cell survival. Further-
*p,0.001 transplanted PARP inhibitor treated, or untreated, samples compared to control PARP inhibitor treated, or untreated control samples.
**p,0.05 untreated transplanted kidney samples compared to PARP inhibitor treated transplanted kidney samples. The vertical axes represent pixel
volume means6SEM of the scanned bands of the immunoblots in arbitrary units.
doi:10.1371/journal.pone.0081928.g005
Figure 6. Effect of PARP inhibitor on activation and phosphorylation of ERK1/2, JNK1/2 and p38 MAP kinase pathways in
transplanted and control kidney samples. (A) Effects of PARP inhibitor on the ERK1/2, JNK1/2 and p38 MAP kinase phosphorylation and
activation in control and transplanted kidneys determined by immunoblotting with phospho-specific primary antibodies. Actin was used as loading
control (B) The bar diagrams represent pixel volumes of ERK1/2 phosphorylation bands. The bands were normalized to the appropriate actin band.
(p-ERK1) *p,0.001 control PARP inhibitor treated samples compared to control samples. **p,0.01 control PARP inhibitor treated samples compared
to transplanted kidney samples independently from PARP inhibitor treatment. ***p,0.05 control untreated sample compared to transplanted kidney
samples independently from PARP inhibitor treatment. (p-ERK2) *p,0.001 control PARP inhibitor treated samples compared to control samples.
**p,0.01 control PARP inhibitor treated samples compared to transplanted kidney samples independently from PARP inhibitor treatment. ***p,0.05
control untreated sample compared to transplanted kidney samples independently from PARP inhibitor treatment. The bar diagrams represent pixel
volumes of p-p38 MAK kinase phosphorylation bands. The bands were normalized to the appropriate actin band. *p,0.001 control samples
compared to transplanted kidney samples (independently of PARP inhibitor treatment). **p,0.05 untreated transplanted kidney samples compared
to control PARP inhibitor treated transplanted kidney samples. The bar diagrams represent pixel volumes of phosphorylated JNK1/2 bands. The
bands were normalized to the appropriate actin band. (p-JNK1) *p,0.05 transplanted untreated kidney samples compared to all others samples. (p-
JNK2) **p,0.001 control kidney samples (independently of PARP inhibitor treatment) comparing to transplanted samples. ***p,0.05 transplanted
untreated kidney samples compared to transplanted PARP inhibitor treated kidney samples. The vertical axes represent pixel volume means6SEM of
the scanned bands of the immunoblots in arbitrary units.
doi:10.1371/journal.pone.0081928.g006
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more, we demonstrated that t-Bid, a highly apoptotic protein,
formed in large quantities in transplanted kidneys compared to
control tissues. The PARP inhibitor significantly decreased this
quantity (Fig. 3A, B) indicating a novel anti-apoptotic pathway for
PARP inhibition. Although the importance of t-Bid in graft
survival has not yet been studied, our data indicate a role for the
molecule to promote cell death in transplanted kidneys.
Studying the signaling pathways in transplanted kidneys, we
found PARP inhibitors activate the cytoprotective PI-3-K-Akt
pathway (Fig. 5A, B), which contributes to graft survival and
preservation of tubulointerstitial structures (Fig. 1A, [58]). PARP
inhibitor induced Akt activation was first demonstrated by Veres et
al. indicating a protective role in septic shock [17,20]. PI-3-K-Akt
pathway plays a significant role in the protection of mitochondrial
membrane system and in the inhibition of cell death pathways
during oxidative stress [46,59]. Therefore, PARP inhibition
induced activation of Akt may have significant role in kidney
graft survival. The regulation of NF-kappaB is complex. Similarly
to that of others [60], our data indicate a parallel behavior for Akt
and NF-kappaB activation (Fig. 4). Thus, it is likely that Akt
initiated NF-kappaB activation may contribute to the survival of
transplanted kidneys under our experimental conditions. The
effect of PARP inhibition on the MAP kinases was also
determined. Our results indicate modest alterations in ERK1/2
and p38 MAP kinase pathways, while PARP inhibition signif-
icantly suppressed the JNK1/2 activation in transplanted kidneys
(Fig. 6A, B). This may also have significance during rejection since
JNK1/2 promotes mitochondrial permeability transition and cell
death [61]. Our observations correspond with previous data
showing PARP inhibitors suppress JNK activation in oxidative
stress [25,61]. Also, since JNK1 activation negatively affects graft
survival [62-64], JNK1 inhibition may play a positive role in
transplanted kidneys. We predict PARP inhibition possesses
similar positive effects as JNK inhibitors by indirectly suppressing
JNK1/2 in transplants. The mechanism, by which PARP
inhibitors suppress JNK activation can be mediated by PARP
inhibition induced MAP kinase phosphatase-1 activation as we
demonstrated before [19]. Therefore, the disintegration of the
tubulointerstitial structures in transplanted kidneys can be at least
in part the consequence of JNK1/2 activation induced cell death.
Moreover, since hypoxia activates JNK1/2 through the Ask1-
MEKK4/7-JNK1/2 pathways, JNK1/2 activation in transplanted
kidneys is most likely a consequence of ischemia-reperfusion,
inflammatory cytokines and monocyte/macrophage induced
oxidative stress.
In conclusion, rejection in transplanted kidneys during early and
late phases is induced in a large extent by oxidative stress of diverse
sources (e.g. ischemia-reperfusion, inflammatory cytokines and
monocytes/macrophages). Inflammation or modulation of signal-
ing cascades that lead to mitochondrial damages facilitate pro-
apoptotic and necrotic processes and result in loss of nephrons or
impairment of tubulo-interstitial structures. Our work demon-
strates that, oxidative stress activates PARP, which initiates cell
death and shifts kinase cascades by suppressing the cytoprotective
PI-3-kinase-Akt pathway and by activation of JNK. The
alterations promote mitochondria mediated cell death that
significantly contributes to kidney graft rejection. The inhibition
of PARP reverses these processes and shifts Bcl-2/Bax ratio into
the cytoprotective direction. The protective mechanisms of PARP
inhibitors are markedly different from that of the widely used
immunosuppressive therapies. Our results suggest the supplemen-
tation of immunosuppression with PARP inhibitors could provide
a novel way to prolong graft survival.
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